|
|
Post by notamnkdmillionaire on Sept 27, 2015 16:34:35 GMT -5
How badly could they get this wrong? Hopefully Sanofi picks up on these glaring errors and has someone in charge of correcting these damaging inaccuracies? I know many are against shorting on here but maybe some might want to consider shorting the SOBs for getting Afrezza so wrong. And they call themselves a health info website. The ticker is EVDY. FWIW, the description of Afrezza when you look it up in their drug database is correct which is even more of a reason to short the bastards for getting it so wrong! I looked to see if any big pharma is supporting them but couldn't find anything. |
|
|
|
Post by harrys on Sept 27, 2015 17:10:16 GMT -5
We need to find out a way to point that out to the website. This is seriously misleading. I just sent an email to the editor: editor@everydayhealth.com
Please everybody do the same! |
|
|
|
Post by compound26 on Sept 27, 2015 17:33:37 GMT -5
We need to find out a way to point that out to the website. This is seriously misleading. I just sent an email to the editor: editor@everydayhealth.com
Thanks, I have also sent an email to editor@everydayhealth.com. |
|
|
|
Post by suebeeee1 on Sept 28, 2015 0:00:07 GMT -5
One may suspect Everyday Health of owning a short position on MNKD themselves.
|
|
|
|
Post by tripoley on Sept 28, 2015 7:39:21 GMT -5
Since when is Afrezza considered "regular-acting"?! I know they can't claim it's "Ultra-fast acting" but to place it a step below the "rapid-acting" injectables... Geez They have the rapid-acting insulins wrong as well. The RAAs don't begin acting in 15 minutes and peak in an hour. Only Afrezza does that. In fact they have them backwards and should kick the regular insulins into a separate category. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 28, 2015 11:42:39 GMT -5
|
|
|
|
Post by mssciguy on Sept 28, 2015 11:53:37 GMT -5
Since when is Afrezza considered "regular-acting"?! I know they can't claim it's "Ultra-fast acting" but to place it a step below the "rapid-acting" injectables... Geez They have the rapid-acting insulins wrong as well. The RAAs don't begin acting in 15 minutes and peak in an hour. Only Afrezza does that. In fact they have them backwards and should kick the regular insulins into a separate category. Maybe when the clamp study results are published??? Wouldn't endos have a moral obligation to prescribe prandial insulin that acts faster and reduces hypoglycemia chances to near zero? FDA did not give us fair treatment. |
|
|
|
Post by harrys on Sept 28, 2015 12:25:37 GMT -5
They have the rapid-acting insulins wrong as well. The RAAs don't begin acting in 15 minutes and peak in an hour. Only Afrezza does that. In fact they have them backwards and should kick the regular insulins into a separate category. Maybe when the clamp study results are published??? Wouldn't endos have a moral obligation to prescribe prandial insulin that acts faster and reduces hypoglycemia chances to near zero? FDA did not give us fair treatment. Moral obligation is not a thing in western medicine... it's all about the kickbacks and cash. |
|
|
|
Post by mssciguy on Sept 28, 2015 13:46:07 GMT -5
harrys It depends upon the doctor, I suppose. Some docs will prescribe almost anything for a buck, others, like mine, only as a last resort. I really really REALLY look forward to reviews by endos from Mayo, Cleveland Clinic,etc, by year end, or maybe next year... enough statistics will be in by then to give a ringing endorsement.
|
|
|
|
Post by tripoley on Sept 28, 2015 14:38:03 GMT -5
Maybe when the clamp study results are published??? Wouldn't endos have a moral obligation to prescribe prandial insulin that acts faster and reduces hypoglycemia chances to near zero? FDA did not give us fair treatment. Moral obligation is not a thing in western medicine... it's all about the kickbacks and cash. The clamp studies will help. As far as I know MNKD compared multiple doses of Afrezza via Dreamboat (10, 30, 60 and 80 units) to regular insulin and compared a single dose and multiple dose via Medtone (30 units vs. two 15 unit doses) with Humalog. So comparing equivalent doses head to head might help with ultra-rapid acting designation. |
|
